Gapping up
News:
- BCRX +5.8% (INESSS has issued a positive recommendation for PrORLADEYO to be reimbursed for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years of age and older in Quebec)
- HUT +5.2% (provides update on business combination with USBTC: obtains final order for plan of arrangement from the Supreme Court of British Columbia)
- SLI +3.1% (announces that the Preliminary Feasibility Study for the South West Arkansas Project; Files Technical Report for the South West Arkansas Project)
- EPIX +1.9% (Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer)
- GSK +1.2% (receives FDA approval for Ojjaara)
- CF +1.1% (issues investor presentation slides)
- LICY +0.9% (Li-Cycle and Glencore (GLNCY) accelerate operational plans for European Recycling Hub)
- BRY +0.9% (completes acquisition of Macpherson Energy; updates annual guidance)
Analyst comments:
- ZIM +3.5% (upgraded to Overweight from Neutral at JP Morgan)
- SMPL +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- AIN +1.4% (upgraded to Outperform from Market Perform at TD Cowen)
- LHX +1% (upgraded to Overweight from Equal Weight at Wells Fargo)